Clinical trial
Temozolomide in Treating Patients With Recurrent Malignant Glioma
NCT00004113 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004113 |
|---|---|
| Title | Temozolomide in Treating Patients With Recurrent Malignant Glioma |
| Official title | A Phase II Study of Temozolomide (SCH 52365, Temodal(R)) for the Treatment of Recurrent Malignant Glioma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | temozolomide |
| Start date | Jun 1, 1999 |
| Primary completion | Oct 1, 2001 |
| Completion | Oct 1, 2001 |
| First posted | May 21, 2004 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: